A Case of Cancer Therapeutics-Related Cardiac Dysfunction Developed in a Patient Treated With Chemotherapy for Breast Cancer

DOI
  • Fujii Tomomasa
    Junior resident, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Masada Kenji
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Kanegawa Munehiro
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Kashiwabara Ayano
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Sumimoto Yoji
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Shimonaga Takashi
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Kinoshita Haruyuki
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Oka Toshiharu
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Zaitsu Junichi
    Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Kuraoka Kazuya
    Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Sugino Hiroshi
    Department of Cardiology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center

Bibliographic Information

Other Title
  • 乳癌術後化学療法中にうっ血性心不全を発症したがん治療関連心機能障害の1例

Search this article

Abstract

<p>　症例は65歳女性．X−1年1月左乳癌stageⅡBと診断され，左乳房切除術後，ドキソルビシン，シクロホスファミド，トラスツズマブなどによる化学療法を施行していた．X年3月より労作時の息切れが出現したため当院を受診した．胸部X線画像で心拡大と両側胸水貯留を認め，心臓超音波検査にて化学療法開始前と比較し左室駆出率の低下（59％から40％）を認め，うっ血性心不全の診断で当院に入院した．Heart failure with reduced ejection fraction（HFrEF）に準じた治療を行い，カルベジロール，エナラプリル，スピロノラクトンの導入を行った．冠動脈造影検査では有意狭窄を認めず，臨床的にがん治療関連心機能障害（cancer therapeutics-related cardiac dysfunction；CTRCD）と診断した．タイプ1に分類されるドキソルビシン，シクロホスファミドとタイプ2に分類されるトラスツズマブの併用歴のある患者に発症したCTRCDの1例を報告する．</p>

Journal

  • Shinzo

    Shinzo 54 (7), 814-820, 2022-07-15

    Japan Heart Foundation

Keywords

Details 詳細情報について

Report a problem

Back to top